 |
| Glaxo Facebook page - covered in garlands. |
Glaxo are at it again. Selective reporting that covers them in garlands.
Many readers will know that I follow the GlaxoSmithKline Facebook page with an avid interest. They rarely respond to comments I leave, to debate with me would, "...contravene our Facebook terms of use policy."
Since when have Glaxo adhered to terms of use... or any other policy for that matter!
Today sees Glaxo bigging themselves up regarding their partnership with the World Anti-Doping Agency (WADA), whom I've wrote about before, here , here and here.
Glaxo seem to be enthralled that The New York Times have picked up on this partnership. They write [fig 1]
The New York Times published an article looking at our partnership with the World Anti-Doping Agency (WADA). We’re working with WADA to evaluate all the medicines we have in development for their performance-enhancing potential. Our aim is to make sure our medicines are never abused by athletes.
 |
| fig 1 |
Which action, akin to a bad defence lawyer unwittingly opening a line of questioning that's best left suppressed, left the door open for me to highlight other occasions where The New York Times had mentioned GlaxoSmithKline, something that I did a lot of in my book, The evidence, however, is clear...the Seroxat scandal.
For those of you that have never read my book here's some of The New York Times articles that Glaxo definitely won't be posting on their Facebook page.
F.D.A. Pulls a Drug, And Patients Despair
Glaxo's Lotronex was taken off the market on Nov. 28, less than 10 months after being approved by the Food and Drug Administration. About 300,000 people had taken it. It was withdrawn because about 70 patients had developed severe constipation or ischemic colitis, a lack of blood flow to the colon. Some needed surgery, including one woman who had to have her entire colon removed. There were five deaths, including three possibly linked to the drug
Sole Lyme Vaccine Is Pulled Off Market
With tick season approaching, the maker of the nation's only vaccine against Lyme disease pulled it off the market, citing poor sales. The vaccine, Lymerix, had caused controversy in recent years, as patients said they were sickened by it and asked the government to restrict sales. Some filed lawsuits against the maker, GlaxoSmithKline.
Investigators Find Repeated Deception in Ads for Drugs
Since 1997, the report said, the F.D.A. "has issued repeated regulatory letters to several pharmaceutical companies, including 14 to GlaxoSmithKline.
What You Do Know Can't Hurt You
What is disturbing about the recent report is that the purported link between Paxil and suicidal thinking comes from an unpublished study sponsored by the Paxil's manufacturer, GlaxoSmithKline. In fact, GlaxoSmithKline has published only one of its nine studies of Paxil in children and adolescents to date.
New York Sues Maker of Antidepressant Drug Paxil
The New York State attorney general accused the British drug giant GlaxoSmithKline of consumer fraud today, asserting that the company had withheld negative information and misrepresented data about the efficacy and safety of prescribing the antidepressant drug Paxil to children.
There's many more here, page after page of articles reporting fraud, tax evasion, corruption, dodgy clinical trials and much more.
Thanks to the GlaxoSmithKline Facebook administrators for opening the door of rebuttal.
JOIN THE FIDDAMAN BLOG ON FACEBOOK
No comments: